Contrasting Quantum Biopharma (NASDAQ:QNTM) & ASLAN Pharmaceuticals (NASDAQ:ASLN)

Quantum Biopharma (NASDAQ:QNTM) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Quantum Biopharma and ASLAN Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	0	0	0	0	0.00
ASLAN Pharmaceuticals	0	0	2	0	3.00

ASLAN Pharmaceuticals has a consensus target price of $76.00, indicating a potential upside of 12,566.67%. Given ASLAN Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe ASLAN Pharmaceuticals is more favorable than Quantum Biopharma.

Insider and Institutional Ownership

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Quantum Biopharma and ASLAN Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-84.21%	-62.63%
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

Volatility & Risk

Quantum Biopharma has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.

Earnings and Valuation

This table compares Quantum Biopharma and ASLAN Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$17.90 million	($15.41)	-0.22
ASLAN Pharmaceuticals	$12.00 million	0.10	-$44.22 million	($21.92)	-0.03

Quantum Biopharma has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Quantum Biopharma is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

ASLAN Pharmaceuticals beats Quantum Biopharma on 7 of the 12 factors compared between the two stocks.

About Quantum Biopharma

Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.